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The Crohn’s Disease Protein, NOD2,
Requires RIP2 in Order to Induce
Ubiquitinylation of a Novel Site on NEMO
negative regulation of that initial inflammation. Thus,
Crohn’s disease manifests as a disease in which both
pro-inflammatory and anti-inflammatory pathways are
faulty [1]. There is a significant environmental influence
on the development of Crohn’s disease, but a genetic
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Harvard Medical School element also plays a role; at least five separate genetic
loci have been linked to Crohn’s disease [1].Boston, Massachusetts
2Division of Signal Transduction The function of the first of these genes to be cloned,
nod2 (card15), highlights thebiphasic nature of the faultyDepartment of Medicine
Beth Israel Deaconess Hospital immune response seen in Crohn’s disease [3, 4]. nod2
encodes a protein with three distinct signaling domains.Boston, Massachusetts
3Department of Systems Biology TheN terminus contains twoCARDs (caspase activation
recruitment domains) that are likely involved in hetero-Harvard Medical School
Boston, Massachusetts philic protein-protein interactions. The center of NOD2
contains an ATP-dependent oligomerization domain,
and the C terminus of NOD2 contains ten leucine-rich
repeats (LRR) [5]. The function of the LRRs has beenSummary
controversial [6]. Although initially thought to bind di-
rectly to LPS [3, 7], the LRRs have subsequently beenBackground: Crohn’s disease is an autoimmune inflam-
shown to bind to the peptidoglycan breakdown product,matory disorder of the gastrointestinal tract and is char-
MDP [8, 9]. Because MDP is not cell permeable andacterized clinically by dysregulation of both pro-inflamma-
because NOD2 is a cytoplasmic protein, current modelstory and anti-inflammatory cytokine signaling networks.
hypothesize that NOD2 acts as an intracellular MDPThe function of the Crohn’s disease protein, NOD2, high-
receptor that is either presented from phagocytosedlights the biphasic nature of the pathology of Crohn’s
bacteria or from an intracellular bacterial infection [10].disease. NOD2canboth strongly activate and negatively
Upon binding to MDP, NOD2 oligomerizes and binds toattenuate NF-kB signaling. The biochemical mechanism
the scaffolding kinase RIP2 (RICK, CARDIAK). RIP2 thenfor this dual function of NOD2 is unknown.
oligomerizes to transmit NOD2’s signal directly to theResults: We demonstrate that NOD2 activation leads
IKK complex, leading to activation of the NF-kB signal-to ubiquitinylation of NEMO, a key component of the NF-
ing pathway [11].kB signaling complex. This ubiquitinylation is agonist
NOD2’s role in the NF-kB pathway has been confus-dependant, and it does not regulate proteosomal de-
ing. Although NOD2 strongly activates NF-kB in tran-struction of NEMO. We show the NOD2-dependent ubi-
sient transfection assays [3, 5, 12] and although Crohn’squitinylation of NEMO is dependent on the scaffolding
disease-associated polymorphisms of NOD2 lose thisprotein kinase RIP2. Crohn’s disease-associated poly-
ability [3, 4, 12], the clinical pathophysiology suggestsmorphisms of NOD2 show a decreased ability to bind
that the opposite should be true [1]. Crohn’s diseaseRIP2, and this decreased ability to bind RIP2 correlates
patients show increased NF-kB activity, and NF-kB in-with a decreased ability to ubiquitinylate NEMO. We
hibitors are used clinically to ameliorate Crohn’s diseasemap the site of NEMO ubiquitinylation to a novel NEMO
symptoms [2, 13, 14]. Insight was gained recently whenubiquitinylation site (Lysine 285) and show that this ubiq-
it was shown that NOD2 could negatively attenuate NF-uityinylation occurs in vivo. Lastly, we show functionally
kB signaling in response to Toll-like Receptor 2 (TLR2)that RIP2-induced ubiquitinylation of NEMO is at least
activation [15]. These in vivo data, coupled with the priorin part responsible for RIP2-mediated NF-kB activation.
biochemical data, suggest that NOD2 may function toConclusions: These data suggest that this novel mode
both positively and negatively attenuate NF-kB signal-of regulation of the NF-kB signaling pathway could be
ing; thus, NOD2’s function may depend on the circum-a factor underlying the pathogenesis of Crohn’s disease.
stance surrounding its activation [16]. Currently, the bio-
chemistry underlying this dichotomous nature of NOD2
Introduction is unknown.
The scaffolding kinase RIP2 is necessary for proper
Crohn’s disease is an inflammatory disorder that is char- NF-kB signaling in response to activation of NOD2 [17].
acterized histologically by transmural inflammation, epi- Previouswork has suggested that RIP2 serves this func-
thelial ulceration, fissure formation, and stenosis of seg- tion via an “induced proximity” model in which RIP2
ments of the entire gastrointestinal tract [1]. Crohn’s coordinates the formation of a large complex between
disease is thought to result from an inappropriate host NOD2 and the IKK kinase complex (IKK, IKK, and
immune response to the normal gastrointestinal bacte- NEMO) [11]. In support of this model, the kinase activity
rial flora [1, 2]. In Crohn’s Disease, there is both too of RIP2 is not necessary for NF-kB activation because
much initial acute inflammation and too little subsequent RIP2 appears to directly bind to multiple members of
the IKK signaling complex to help mediate complex for-
mation [11, 18–20]. Given RIP2’s function to couple*Correspondence: lewis_cantley@hms.harvard.edu
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NOD2 to the IKK signaling complex [11], it has been for NF-kB activation [18–20]. To determine the effect
of RIP2’s kinase activity on NEMO ubiquitinylation, weproposed that RIP2 serves as a key mediator to deter-
mine whether NOD2 functions in a positive or negative transfected a kinase-dead version (K47A RIP2) of RIP2
into cells in the presence of K399R NEMO and HA-manner inNF-kBsignaling [16]. However, the complexity
of this signaling pathway suggests that in addition to ubiquitin. BothRIP2andK47ARIP2 induced theubiquiti-
nylation of NEMO (Figure 1B). This finding is consistentacting as a nucleating factor, RIP2 may have other func-
tions. The ability of RIP2 to nucleate the IKK signalo- with previous findings showing that RIP2 functions as
a scaffolding protein to activate NF-kB; RIP2’s kinasesome does not account for the complexity of signaling
initiated by NOD2 [10]. activity is dispensable for NF-kB activation [18–20].
Ubiquitin conjugation has been most prominently as-In this work, we have studied the effect of NOD2 and
RIP2 on the IKK signaling complex. We show that both sociated with protein degradation, but it is becoming
increasingly recognized that ubiquitinylation plays a keyRIP2 and NOD2 strongly induce the ubiquitinylation of
NEMO, a key component of the IKK signaling complex. role in cell signaling (reviewed in [24]). To determine
if RIP2-induced NEMO ubiquitinylation causes NEMOThis ubiquitinylation occurs in an agonist-dependent
manner, and Crohn’s disease-associated polymor- degradation via the proteosome, we transfected cells
with either wild-type NEMO or K399R NEMO in the pres-phisms of NOD2 lose the ability to ubiquitinylate NEMO.
siRNAexperiments show that RIP2 is required for NOD2- ence or absence of RIP2. 24 hr after transfection, cells
were exposed to the proteosome inhibitor MG132 or toinduced NEMO ubiquitinylation, and the Crohn’s dis-
ease-associated NOD2 polymorphisms that cannot vehicle control. Lysates were made, and Western blots
were performed. A -catenin blot served as a positiveubuiquitinylate NEMO show a decreased ability to bind
RIP2. We map the ubiquitinylation site of NEMO to a control for MG132’s inhibition of the proteosome (Figure
2A) and showed that the hyperphosphorylated, nonde-novel site (lysine 285) and show by mass spectrometry
that this ubiquitinylation occurs in vivo. Lastly, we show graded form of -catenin was present in the presence
of MG132 (Figure 2A). NEMO expression was essentiallythat the K63 deubiquitinylating enzyme CYLD can re-
verse RIP2-mediated NEMO ubiquitinylation and that unchanged in the presence or absence of MG132, indi-
cating that NEMO ubiquitinylation likely did not lead toCYLD can strongly inhibit RIP2-induced NF-kB activa-
tion. Collectively, these data suggest that this novel proteosomal degradation (Figure 2A). Because of this
experiment, we considered the possibility that NEMOmodeof regulationof theNF-kBsignalingpathwaycould
be one factor underlying the pathogenesis of Crohn’s was ubiquitinylated to influence signaling pathways
rather than proteosomal degradation.disease.
Ubiquitin contains seven lysines that can be cova-
lently linked in polyubiquitin chains, and which lysine is
Results and Discussion linked often determines function [24]. For instance, K48-
linked chains typically lead to proteosomal degredation
RIP2 Induces K63-Linked Ubiquitinylation of the linked protein [24]. To determine which ubiquitin
of NEMO at a Novel Site of Attachment chainwas formedonNEMO,we utilized amutant version
In the course of studying RIP2’s effect on NF-kB and of ubiquitin in which all of the lysines were mutated to
coexpressing both RIP2 and NEMO, we found that RIP2 non-ubiquitin-chain-forming arginine with the exception
induced a large (8 kDa) mobility shift in NEMO (Figure of a single target lysine. In all, K6-, K11-, K29-, K48-, and
S1). Given the size of the shift, we hypothesized that K63-only ubiquitin mutants were used in the experiment
this shift was due to NEMO ubiquitinylation. To investi- (limited expression of K27-only and K33-only ubiquitin
gate this, we coexpressed NEMO with HA-tagged ubi- has been shown [25], and therefore these were not used
quitin in either the presence or absence of RIP2. NEMO in this experiment). K399R NEMO was expressed with
was immunoprecipitated, and Western blots were per- RIP2 in thepresence of each of thesemutants. Only K63-
formedwith an anti-HA antibody.When expressed, RIP2 ubiquitin could link in polyubiquitin chains on NEMO.
consistently led to a 20%–40% increase in the amount Because K63-linked ubiquitin chains have been shown
of ubiquitinylated NEMO (Figure 1A; compare lanes 2 to be important in NF-kB signaling [21, 22, 24, 26], this
and 3). NEMO has been shown to be ubiquitinylated in experiment suggests that RIP2-induced ubiquitinylation
response to T cell receptor (TCR) engagement [21, 22] of NEMO functions to influence NEMO signaling.
and in response to exposure to TNF- [23], and in these
studies, ubiquitinylation of lysine 399 was required for
optimal NF-kB activity [21, 23]. To determine if RIP2 was NOD2 Activation Causes NEMO Ubiquitinylation,
and this Activity Is Lost in Crohn’s Disease-inducing ubiquitinylation of K399, we mutated K399 to
arginine. Surprisingly, although baseline ubiquitinylation Associated NOD2 Polymorphisms
Because the Crohn’s disease protein NOD2 requiresof NEMO decreased substantially (Figure 1A, lane 4),
RIP2 strongly induced ubiquitinylation of the K399R RIP2 to signal to the IKK signaling complex [17], we
wanted to determine if NOD2 activation correlated withNEMO mutant (Figure 1A, lane 5). This result suggests
that RIP2 induces ubiquitinylation of NEMO at a novel NEMOubiquitinylation.We alsowanted to determine the
effect of Crohn’s disease-associated polymorphisms onsite.
RIP2 is a dual-function protein that serves as both a this NEMO ubiquitinylation. NOD2 was expressed with
K399R NEMO in the presence of HA-ubiquitin. Withoutscaffolding protein and a serine-threonine protein ki-
nase [18–20]. The function of the kinase domain is un- activation, NOD2 showed little NEMO ubiquitinylation
(Figure 3, lane 4). The NOD2 agonist, MDP, has limitedknown, and kinase activity appears to be dispensable
NOD2 Causes Novel NEMO Ubiquitinylation
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Figure 1. RIP2 Induces the Ubiquitinylation of a Novel Site in NEMO
(A) Omni-tagged RIP2 was coexpressedwith wild-typeMyc-tagged NEMOor K399RMyc-tagged NEMO in the presence of HA-tagged ubiquitin.
Wild-type or K3999R NEMO was immunoprecipitated with the Myc antibody (9E10), and Western blots were performed with the indicated
antibody.
(B) Omni-tagged RIP2 or Omni-tagged K47A RIP2 was coexpressed with Myc-tagged K399R NEMO and HA-tagged ubiquitin. K399R NEMO
was immunoprecipitated, and Western blots were performed with the indicated antibodies.
cell permeability but can be transfected into the cell lation of NEMO (Figure 3, lane 5). Similar experiments
were performed with the Crohn’s disease-associatedvia calcium phosphate transfection [8, 9]; therefore, we
cotransfected NOD2 with its agonist, MDP. The pres- NOD2 polymorphisms/mutations. L1007insC is a loss-
of-function polymorphism associated with traditionalence of MDP and NOD2 strongly induced the ubiquitiny-
Figure 2. RIP2-Induced NEMO Ubiquitinylation Does Not Lead to Proteosomal Degredation but Instead Induces the Formation of a K63-
Linked Polyubiquitin Chain on NEMO
(A) Myc-tagged wild-type or Myc-tagged K399R NEMO were expressed in the presence or absence of RIP2. Cells were exposed to 10 M
of the proteosome inhibitor MG132 overnight or to vehicle control (DMSO). Lysates were analyzed by Western blotting with the indicated
antibody. As a positive control, -catenin expression was analyzed. An actin blot was used to show equal loading.
(B) RIP2 was coexpressed with Myc-tagged K399R NEMO in the presence of HA-tagged wild-type ubiquitin, HA-K6-only ubiquitin, HA-K11-
only ubiquitin, HA-K29-only ubuiqutinin, HA-K48-only ubiquitin, or HA-K63-only ubiquitin. NEMO was immunoprecipitated with the anti-Myc
antibody (9E10), and Western blotting was performed with the indicated antibodies.
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Figure 3. NOD2 Induces NEMO Ubiquitinylation in an Agonist-Dependent Manner, and this Induction Is Not Seen with the Crohn’s Disease-
Associated NOD2 Polymorphism
(A) NOD2 or the Crohn’s disease-associated NOD2 polymorphisms were expressed with both Myc-tagged K399R NEMO and HA-tagged
ubiquitin in either the presence or absence of NOD2 agonist MDP. Because of the limited cell permeability of MDP, MDP was included in the
calcium phosphate transfection as described [8, 9]. NEMO was immunoprecipitated, and Western blots were performed with the indicated
antibodies.
(B) THP-1 cells were treated overnight with either 2.5 ng/ml MDP or 25 ng/ml MDP or were left untreated. Each cellular lysate was precipitated
with an anti-NEMO antibody, and Western blots were performed with either an anti-ubiquitin antibody or an anti-NEMO antibody. A lighter
exposure shows the dose responsiveness of the endogenous NEMO ubiquitinylation, and a darker exposure of the same blot shows the
beginnings of the ubiquitinylation laddering at the higher dose of MDP.
Crohn’s disease [3, 4], whereas D291N is a dominant- NOD2 Binding to RIP2 and RIP2 Expression
negative mutant that is associated with a severe form Are Necessary for NOD2 to Induce
of Crohn’s disease [12]. L1007insCNOD2 caused limited Ubiquitinylation of NEMO
NEMOubiquitinylation (Figure 3, lanes 6 and 7.Note: The Because both RIP2 and NOD2 induce NEMO ubiquitiny-
form of NOD2 used (EST cDNA clone IMAGE:5324763) lation and because both NOD2 and RIP2 have been
causes the terminal 41 amino acids to be out of frame reported to bind one another [11], the lack of agonist-
when a C is inserted at this site), whereas expression induced ubiquitinylation seen in the presence of the
of D291N NOD2 showed no NEMO ubiquitinylation (Fig- Crohn’s disease-associated polymorphisms could be
ure 3, lanes 8 and 9). These findings recapitulate the due to a lack of RIP2 binding. To test this, we transfected
clinical phenotype seen with these mutations/polymor- both HA-taggedRIP2 andOmni-tagged NOD2 into cells.
phisms and suggest that NEMO ubiquitinylation may be Immunoprecipitateswerewashedextensivelywithmod-
faulty in genetic Crohn’s disease. ified RIPA buffer, and Western blots were performed
To determine if NOD2 activation causes ubiquitinyla- with the indicated antibodies. RIP2 and NOD2 bound
tion of endogenous NEMO, THP-1 cells were used. strongly to one another under these stringent conditions
THP-1 cells contain a high level ofNOD2byRNAanalysis (Figures 4A and 4B, lane 5, upper blot) when immuno-
[27]. As a result of the limited permeability of MDP, cells precipitated in either direction. In contrast, neither
were treated with 2.5 ng/ml of MDP or 25 ng/ml MDP L1007insC NOD2 nor D291NNOD2 bound to RIP2 under
overnight or were left untreated. Endogenous NEMO
these stringent washing conditions in the agonist-inde-
was immunoprecipitated, and Western blots were per-
pendent state (Figures 4A and 4B, lanes 6–7, upper blot).
formed with both an anti-ubiquitin antibody and an anti-
This effectwas seenunder immunoprecipitation in eitherNEMO antibody. Two exposures of the anti-ubiquitin
direction (anti-HA or anti-Omni), and the negative con-Western blots are shown. The upper, lighter exposure
trols (Figures 4A and 4B, lanes 2–4, upper blot) showedshows that NEMO is ubiquitinylated in response to both
no indirect antibody affinity for either RIP2 or the NOD2low-dose (2.5 ng/ml) and higher-dose (25 ng/ml) MDP
forms. Work in Gabriel Nunez’s laboratory has demon-(Figure 3B, upper blot), whereas the middle, darker ex-
strated that although the CARD domains in NOD2 areposure shows that ubiquitin laddering begins to occur
sufficient for binding to RIP2, there is a negative self-at the higherMDPdose (Figure 3B,middle blot). Roughly
regulatory region near the LRRs [5, 28]. In the inactiveequal amounts of NEMOwere immunoprecipitated (Fig-
state, this negative regulatory region may mean that theure 3B, lower blot). Because NOD2 is the only known
CARD domains of NOD2 are less accessible to bindcellular protein to be responsive to MDP [8–10] and
RIP2 and that uponMDPbinding, this negative inhibitionbecause even the highly related PAMP binding protein
is relieved, making the CARD domains more accessible.NOD1 does not respond to MDP [8–10], these results
The loss of function of both the L1007insC and D291Nsuggest thatMDP activates endogenousNOD2 to cause
ubiquitinylation of NEMO. polymorphisms may be due to an exaggerated negative
NOD2 Causes Novel NEMO Ubiquitinylation
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regulatory state, as exemplified by the loss of RIP2 bind-
ing by these mutants in this overexpression study.
As in Figures 4A and 4B, studies in other laboratories
have also shown that overexpression of NOD2 allows
NOD2 to bind to RIP2 in the unstimulated state through
heterophillic CARD domain interactions [5, 11]. To more
fully mimic the physiologic activation of NOD2 and to
determine the effect of the NOD2 agonist, MDP, on the
binding of RIP2 to NOD2 or the NOD2 polymorphisms,
we performed a similar experiment to that shown in
Figures 4A and 4B, only with limiting amounts of NOD2
and in the presence of NOD2 agonist MDP (introduced
via calcium phosphate precipitation). NOD2 or its vari-
ants were immunoprecipitated, and the presence of
RIP2 was detected with an anti-HA antibody. Under
stringent washing conditions, consistently less RIP2
was associated with the Crohn’s disease-associated
polymorphisms (Figure 4C). These findings strongly sug-
gest that theCrohn’s disease-associated formsof NOD2
have less affinity for RIP2, and this feature may explain
the lack ofNEMOubiquitinylation inducedby thesepoly-
morphic forms.
If RIP2binding is indeed necessary forNOD2 to induce
the ubiquitinylation of NEMO, then inhibition of the ex-
pression of RIP2 should lead to decreased NOD2-induced
NEMO ubiquitinylation. We used siRNA to knock down
expression of RIP2. As a control for proper knockdown
of RIP2, HA-tagged RIP2 was transfected into cells
along with the control constructs HA-tagged IKK and
HA-tagged RIP2CARD. The siRNA was targeted
against the CARD domain of RIP2, and for this reason,
a form of RIP2 lacking the CARD domain (RIP2CARD)
was used as a control. These constructs were trans-
fected into cells along with various concentrations of
control siRNA or RIP2 siRNA. Lysates were made, and
Western blots were performed with the HA antibody.
Figure 5A shows that at all concentrations of RIP2, siRNA-
tested expression of the HA-RIP2 protein was reduced.
The control transfections (HA-IKK and HA-RIP2
CARD) showed no knockdown (Figure 5A). To determine
if endogenous RIP2 was necessary for NOD2-induced
NEMO ubiquitinylation, we transfected NOD2 and its
agonist, MDP, into cells along with K399R NEMO and
HA-ubiquitin. Either the control siRNA or the RIP2 siRNA
was included in the transfection. Without any siRNA,
NOD2 and MDP induced a strong ubiquitinylation of
NEMO (Figure 5B, lane 1). The control siRNA induced
an increase in NEMO ubiquitinylation, possibly due to
a nonspecific RNAi effect. NOD2’s agonist-dependent
ubiquitinylation of NEMO was nearly abolished in the
presence of siRNA directed against RIP2 (Figure 5B,
lane 3). This finding suggests that RIP2 is necessary
Figure 4. RIP2 Binds Strongly to Wild-Type NOD2, but with Much
Less Affinity to the Crohn’s Disease-Associated NOD2 Polymor- precipitated under stringent conditions (five washes with RIPA
phisms L1007insC and D291N buffer) with an anti-HA antibody, and Western blots were performed
(A) HA-tagged RIP2 was expressed with Omni-tagged wild-type with the indicated antibodies.
NOD2, L1007insCNOD2, or D291NNOD2. NOD2 or the polymorphic (C) HA-tagged RIP2 was expressed with Omni-tagged wild-type
NOD2s were immunoprecipitated with an anti-Omni antibody under NOD2, L1007insC NOD2, or D291N NOD2. Transfections were per-
stringent conditions (five washes with RIPA buffer), and Western formed in the presence of the NOD2 agonist, MDP. NOD2 or the
blots were performed with the indicated antibodies. Crohn’s disease-associated polymorphisms were stringently immu-
(B) Again, HA-tagged RIP2 was expressed with Omni-tagged wild- noprecipitated with the anti-Omni antibody, and Western blots were
type NOD2, L1007insC NOD2, or D291N NOD2. RIP2 was immuno- performed with the indicated antibodies.
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the complexity of the search for the ubiquitinylation site,
we initially used a genetic approach. RIP2 is conserved
in zebrafish, but not in Drosophila. We identified the
zebrafish NEMO and compared its sequence to human
NEMO. Only four lysines are conserved (K115, K224,
K285, and the previously mutated K399) (Figure 6A).
K115, K224, and K285 were mutated in a K399R back-
ground and expressed in the presence of HA-tagged
ubiquitin. RIP2 caused the induction of NEMO ubiquiti-
nylation in the K115R K399R mutant and the K224R
K399R mutant but caused decreased ubiquitinylation of
the K285R K399R mutant (Figure 6B). These data imply
that K285 is a major site of RIP2-induced ubiquitinyla-
tion; however, the lack of NEMO ubiquitinylation was
not complete, suggesting that additional ubiquitinyla-
tion sites are present.
To verify that K285 is ubiquitinylated in vivo, we coex-
pressed K399R NEMO and RIP2 and immunoprecipi-
tated NEMO. The majority of the NEMO purified was
present at the expected 50–52 kDa size. We also de-
tected several lower-mobility proteins, including a sharp
band with an apparent size of 68 kDa (Figure 6C). This
sharp 68 kDa band was excised and subjected to mass
spectrometry. Ubiquitin-modified lysine does not cleave
with trypsin and shows a characteristic gycine-glycine
signature upon tryptic cleavage [28]. Bymass spectrom-
etry analysis, the 68 kDa band consisted only of NEMO
containing the characteristic ubiquitin signature at lysine
285 (Figure 6D). Given the fact that the K285R K399R
mutant NEMO abolished a large proportion of ubiquiny-
lated NEMO (Figure 2B), we believe that the K285 site
is themajor site of RIP2-inducedNEMOubiquitinylation.
RIP2-Induced NEMO Ubiquitinylation Activates
NF-kB Signaling, and this Activation Can
Figure 5. RIP2 Is Required for NOD2’s Induction of NEMO Ubiquiti- Be Inhibited by Expression of the
nylation K63-Deubiquitinase CYLD
(A) HA-tagged IKK, HA-tagged RIP2, and HA-tagged RIP2CARD In one of the initial papers describing the original cloning
(lacking the CARD domain) were expressed in the presence of in- of NEMO, a biochemical approach was used. In this
creasing concentrations of either control siRNA or RIP2 siRNA (di- work, overexpression of NEMO greatly inhibited NF-kB
rected against RIP2’s CARD domain). Two days after transfection,
activation [30]. Only upon utilizing genetic strategies tolysates were prepared and a Western blot was performed with an
clone NEMOwas it recognized that NEMOwas essentialanti-HA antibody.
(B) Myc-tagged K399R NEMOwas expressed with HA-ubiquitin and for the activation of the NF-kB signaling pathway and
Omni-tagged NOD2 in the presence of NOD2 agonist MDP and in that overexpression of NEMO artifactually causes re-
the presence of either control siRNA or RIP2 siRNA. K399R NEMO pression of NF-kB signaling via an exaggeration of
was immunoprecipitated, and Western blots were performed with NEMO’s scaffolding function [31, 32]. In our preliminary
the indicated antibodies.
studies,we found that overexpressionof all of our NEMO
ubiquitinylation mutants repressed NF-kB signaling to
varying degrees (data not shown). We believe that thisfor NOD2-induced NEMO ubiquitinylation and further
too is an overexpression artifact. To solve this problemimplies that signaling defects characteristic of Crohn’s
and to show functional significance of RIP2-induceddisease could result from the decreased ability of
NEMO ubiquitinylation, we utilized the K63 deubiquiti-Crohn’s disease-associated NOD2 polymorphisms to
nase CYLD. CYLD is the gene product responsible forbind RIP2 and subsequently cause ubiquitinylation of
familial cylindromatosis [32] and has been shown toNEMO.
deubiquitinylate NEMO, TRAF2, and TRAF6 to inhibit
NF-kB signaling [34–36]. To determine if CYLD could
inhibit RIP2-induced NEMO ubiquitinylation, we ex-RIP2 Causes the Ubiquitinylation
of Lysine 285 on NEMO pressed K399R NEMO with HA-ubiquitin, RIP2, and var-
ying amounts of CYLD. Again, K399R NEMO was immu-Given these findings and the possibility that the NOD2-
RIP2 complex induces the ubiquitinylation of a novel site noprecipitated, andWesternblotswereperformed.RIP2
strongly induced the ubiquitinylation of NEMO, but thison NEMO, we wanted to map the NEMO ubiquitinylation
sites. Human NEMO contains 24 lysines. To decrease ubiquitinylation could be reversed in a dose-responsive
NOD2 Causes Novel NEMO Ubiquitinylation
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Figure 6. Lysine-285 Is the Site of the Major RIP2-Induced NEMO Ubiquitinylation
(A) The earliest organism that contains RIP2 is the zebrafish. Comparing the human NEMO and zebrafish NEMO allowed determination of
which lysines were most likely to be ubiquitinylated in response to RIP2 expression. Four (of 24) lysines were conserved (K115, K224, K285,
and K399). The conserved lysines are highlighted within boxes.
(B) Each of the aforementioned conserved lysines was mutated in a K399 background (K115R K399R, K224R K399R, and K285R K399R). All
mutant NEMO constructs were tagged with Myc. Each of the mutants was coexpressed with RIP2 in the presence of HA-tagged ubiquitin.
NEMO was immunopreciptiated with the anti-Myc antibody, and Western blotting was performed with the indicated antibody. Much of the
NEMO ubiquitinylation disappeared in the K285R K399R NEMO mutant.
(C) For biochemical identification of the site of RIP2-induced NEMO ubiquitinylation in vivo, RIP2 and K399R NEMO were coexpressed. NEMO
was immunoprecipitated with the anti-Myc antibody covalently attached to Sepharose beads. Immunoprecipitated proteins were extracted
in 1% SDS after being heated to 60C. Isolated proteins were run on an SDS page gel. Proteins were visualized with Coomassie staining.
(D) The MS/MS spectrum of the peptide QEVIDKLK(114.1)EEAEQHK in NEMO shows the typical b ions (containing N terminus) and y ion
(containing C terminus) series resulting from collision induced dissociation of the triply charged peptide at m/z 647.03. Although all major
ions can be explained by the above sequence, the fragment ions y7 and y8 show that Lys-287 is the site of modification because the m/z
difference between y7 and y8 equals a lysine residue mass (128.1 Da) plus two glycine residue masses (114.1 Da). This is the typical ubiquitin
signature; tryptic cleavage of ubiquitin results in two glycine residues attached to the substrate. The doubly charged y ion series of y10
through y13 confirms the modification of Lys-287 and shows that Lys-285 is not the site of ubiquitination because no mass shift is observed.
manner with the expression of CYLD (Figure 7A). This decrease RIP2’s activation of NF-kB. We took two ap-
proaches to measure the effect of CYLD on RIP2’s NF-kBfinding provides further evidence that RIP2 induces K63
ubiquitinylation and suggests that CYLD can negatively activation. First, we performed NF-kB reporter assays.
RIP2 caused approximately a 7-fold increase in NF-kBregulate RIP2-induced NEMO ubiquitinylation.
The fact that CYLD inhibits the RIP2-induced ubiquiti- activity, and this increase could be inhibited by the ex-
pression of CYLD (Figure 7B). In the second assay, wenylation of NEMO allows us to use CYLD as a tool to
determine if RIP2-induced ubiquitinylation negatively or aimed todetermineCYLD’s effect onRIP2’s activationof
NF-kB by assaying the phosphorylation of the activationpositively influences NF-kB signaling. If NEMO ubiquiti-
nylation negatively regulates NF-kB signaling, then loop of IKK. The phosphorylation of Ser-177 and Ser-
181 on IKK has been shown to be essential for optimalCYLD expression should enhance RIP2’s activation of
NF-kB. Alternatively, if NEMO ubiquitinylation positively IKK activity and can be used to assess IKK activation
[37]. HA-tagged IKK was transfected into cells withregulates NF-kB signaling, then CYLD expression should
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Figure 7. The K63 Deubiquitinase CYLD Negatively Regulates RIP2-Mediated NF-kB Activation
(A) Myc-tagged K399R NEMO was coexpressed with Omni-tagged RIP2 or with increasing amounts of Omni-tagged CYLD. K399R NEMO
was immunoprecipitated with an anti-Myc antibody, and Western blots were performed with the indicated antibodies. The upper blot shows
that CYLD can antagonize RIP2-induced NEMO ubiquitinylation.
(B) NF-kB reporter assays were performed with a commercially available NF-kB SEAP reporter construct (Clontech). RIP2 induced a 7- to
8-fold increase in NF-kB reporter activity, and this increase could be completely abrogated by coexpression of CYLD.
(C) HA-tagged IKK was coexpressed with either RIP2 or with increasing amounts of CYLD. Transfected IKK was immunoprecipitated with
an anti-HA antibody, and Western blots were performed with the indicated antibodies. RIP2 caused an increase in IKK activation loop
phosphorylation, implying increased activity of IKK. This RIP2-induced increase was strongly inhibited in the presence of CYLD.
RIP2, CYLD, or both RIP2 and CYLD. IKKwas immuno- shown to be necessary for full activation of the NF-kB
signaling pathways; the K63 deubiquitinating enzymes,precipitated with an anti-HA antibody, and Western
blots were performed. RIP2 expression increased S177 CYLD and A20, negatively regulate multiple NF-kB sig-
naling pathways [34–36, 38]. To date, NEMO has beenS181 phosphorylation of IKK (Figure 7C). This increased
phosphorylation could be suppressed by coexpression of shown to be ubiquitinylated in response to both TCR
CYLD (Figure 7C). Given that CYLD is known to function stimulation and TNF- exposure, and the site of that
as a K63 deubiquitinase to inhibit the NF-kB signaling ubiquitinylation has been mapped genetically to lysine
pathway, these findings suggest that RIP2-mediated 399 [21–23]. This ubiquitinylation site was shown to be
ubiquitinylation of NEMO is essential for RIP2-mediated necessary for full activation of the NF-kB pathway [21].
NF-kB activation. That the activation of the NOD2-RIP2 signaling pathway
induces the ubiquitinylation of lysine 285 while other
inflammatory stimuli induce the ubiquitinylation of lysineConclusions
399 implies that the ubiquitinylation of NEMOmaymedi-The above data suggest a novel mechanism by which
ate cross-talk between various upstream inflammatoryNF-kB signaling is faulty in Crohn’s disease. Our data
signaling pathways. Because NOD2 activation has beenshow that upon binding to MDP, NOD2 can bind RIP2
shown to downregulate TLR2 signaling, a precedent forand induce NEMO ubiquitinylation at a novel site of
cross-talk between these signaling pathways nowexistsattachment. This ubiquitinylation is essential for RIP2’s
[15]. RIP2 appears to be a central mediator in this poten-activation of the NF-kB signaling pathway. The down-
tial inflammatory cross-talk because it can bind to bothstream effectors for this process could involve either
TLR2 [17] and NOD2 [11] and is required for signalingthe activationof aK63E3ubiquitin ligaseor the inhibition
in both of these signaling pathways [17]. Given that RIP2of a K63 deubiquitinase (model in Figure 7). NEMO’s
K63-linked polyubiquitin chains have previously been causes such strong K63-linked polyubiquitinylation of
NOD2 Causes Novel NEMO Ubiquitinylation
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for transfection with the given expression constructs. For IP-ubiqui-
tination assays, cell lysates were prepared with a buffer containing
50 mM Tris HCL (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM
-glycerophosphate, 5 mM iodoacetimide, 1 mM PMSF, 1 M so-
dium orthovanadate, and 1 M leupeptin. Immunoprecipitations
were performed with anti-Myc (9E10) (Santa Cruz) overnight fol-
lowed by the addition of protein A or protein G. Immunoprecipitates
were washed 5 in lysis buffer. For high-stringency interaction test-
ing between RIP2 and NOD2, lysates were prepared in RIPA buffer
(50 mM Tris-Hcl (pH 7.5), 200 mM NaCl, 0.25% deoxycholic acid,
1% NP-40, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium
pyrophosphate, 1 mM -glycerophosphate, 5 mM iodoacetimide, 1
mM PMSF, 1 M sodium orthovanadate, 1 M leupeptin, and 1
M calyculin). Immuoprecipitations were performed with anti-Omni
(Santa Cruz), anti-HA11 (Roche), or anti-HA polyclonal (Santa Cruz)
antibodies. Precipitates were washed in 50 bed volumes of RIPA
buffer for five total washes. Western blotting and SDS-PAGE were
performed as described [39].
Antibodies, Plasmids, and Reagents
Anti-Myc (9E10), Anti-HA (rabbit), anti-NEMO, and anti-Omni anti-
bodies were obtained from Santa Cruz Biotechnology. The NEMO
antibody used to immuoprecipitate endogenous NEMO was pur-
chased from BD Biosciences. Anit-ubiquitin was obtained from Ab-
cam. Anti-HA11 (mouse) was obtained from Roche. Anti-p177/p181
IKK and anti-IKK antibodies were obtained from Cell Signaling
Technology. HA-tagged RIP2, HA-ubiquitin, HA-K48 ubiquitin, and
HA-K63 ubiquitin were a generous gifts from Vishva Dixit (Genen-
tech). Omni-tagged RIP2 was generated by PCR cloning into
pcDNA4 (Invitrogen). NEMO was obtained from Eric Weiner (Joslin
Diabetes Center) and was PCR cloned into the 3 Myc (pEBB)
expression vector. A mouse NOD2 EST (cDNA clone IM-
AGE:5324763) and a human CYLD (cDNA clone IMAGE:4552767)
were obtained from ATCC and PCR cloned into pcDNA4 (Omni-
tagged). Site-directed mutants were generated by a modification of
the Quickchange (Stratagene) protocol and were sequenced to ver-
ify identity. The NOD2 polymorphism corresponding to the 3020insC
(1007) in human was constructed in the above mouse EST. In this
EST, the insertion of a cytosine at this site causes missense muta-
Figure 8. Model of the Activation of the NOD2-RIP2 Complex and
tions of the next 30 amino acids. For this reason, although the human
Potential Mechanism for the Induction of NEMO Ubiquitinylation
L1007insC truncates 28 amino acids, the mouse L1007insC from
MDP induces NOD2 oligomerization. NOD2 then recruits RIP2 to our clone migrates at a size indistinguishable from the wild-type.
induce multiple RIP2 proteins to be present in high concentrations. To ensure that the L1007insC mutant was behaving similarly to
This locally high concentration encourages the formation of RIP2 published reports, we performed NF-kB reporter assays, whose
oligomers, which then activate either a K63 ubiquitin ligase or a K63 results were similar to those of published reports (data not shown).
deubiquitinating enzyme. Primer sequences used to generate clones and mutants are avail-
able upon request. siRNA directed against RIP2 as well as the con-
trol sirna oligo was obtained from Ambion. MDP was obtained fromNEMO, we believe that this RIP2-induced ubiquitinylation
Bachem.of NEMO is a good candidate for mediating the cross-talk
between these inflammatory signaling pathways.
Mass Spectrometry
Faulty cross-talk between multiple inflammatory sig- Proteins from gel bands were digested with modified trypsin ob-
naling pathways is an attractive hypothesis for the cause tained from Promega (Madison, WI). Extracted tryptic peptides were
of pathogenesis in Crohn’s disease. Given that multiple analyzed by data-dependent reversed-phasemicrocapillary LC/MS/
MS with a ThermoFinnigan (San Jose, CA) LCQ Deca ion trap massimflammatory cell types are present in the gastrointesti-
spectrometer operated in positive-ion mode at a flow-rate of 250nal tract and that multiple cytokine signaling pathways
nl/min and a 75 m (ID)  15 m (ID tip)  5 cm (length) C18 columnare induced in the gastrointestinal tract in active Crohn’s
obtained from New Objective. (Woburn, MA). The Sequest (Thermo-disease [1, 2], dysfunctional communication between
Finnigan, San Jose, CA) algorithm was used for searching all MS/
these cells and their cytokine signaling pathways may MS data for NEMO modified lysine residues that correspond to a
help to explain the dichotomous signaling induced by ubiquitin modification (GG, 114.1 Da). Matching spectra were first
NOD2 activation. Given the clinical implications of the identified by a correlation score to the protein database and were
further validated by manual inspection.mechanism of this ubiquitinylation, future work will be
directed at determining the biochemical mechanism of
Reporter Assaysthis NOD2-RIP2-induced ubiquitinylation.
Twelve-well dishes of HEK-293 cells were transfected with Polyfect
(Qiagen) with 100 ng NF-kB SEAP reporter (Clontech) and 50 ngExperimental Procedures
Omni--Gal with 200 ng Omni-RIP2, 600 ng Omni-CYLD, neither, or
both.Western blotting showed that all Omni-tagged constructswereCell Culture, Transfection, Immunoprecipitations,
expressed appropriately (data not shown). Themedia were changedand Western Blotting
24 hr after transfection. Both cell media and cell lysates were har-HEK-293 cells were obtained from ATCC and were grown in DMEM
containing 10% FBS. Calcium phosphate precipitation was utilized vested 24 hr later. Transfection efficiency was standardized with
Current Biology
2226
-galactosidase activity assays. For measuring SEAP activity, 10 l T., Knuechel, R., Baeuerle, P.A., Scholmerich, J., and Gross, V.
(1998). Nuclear factor kappaB is activated in macrophages andof media was diluted in 50 mM Tris (pH 7.5) to 50 l. This dilution
was incubated at 65C for 40 min so that endogenous alkaline phos- epithelial cells of inflamed intestinal mucosa. Gastroenterology
115, 357–369.phatase activity was inactivated. SEAP Assay Buffer (97 l; Clon-
tech) was added along with 3 l of 1 mM MUP. Fluoresence was 15. Watanabe, T., Kitani, A., Murray, P.J., and Strober, W. (2004).
NOD2 is a negative regulator of Toll-like receptor 2-mediatedmeasured with excitation and emission peaks of 360 nm and 449
nm, respectively. T helper type 1 responses. Nat. Immunol. 5, 800–808.
16. O’Neill, L.A.J. (2004). How NOD-ing off leads to Crohn disease.
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